ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer
ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer Aulos Bioscience to Present at the 39th Annual J.P. Morgan Healthcare Conference BOSTON and TEL AVIV, Israel, Jan. 8, 2021 /PRNewswire/ -- ATP, a leading life sciences venture capital firm, and Biolojic Design, a biotechnology company that computationally designs functional antibodies, today unveiled Aulos Bioscience, a new company that is developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors. ATP has com...
Source: finanznachrichten.de